These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 10635646)

  • 41. Acarbose for type 2 diabetes prevention.
    Scheen AJ
    Lancet; 2002 Nov; 360(9344):1516; author reply 1517. PubMed ID: 12433557
    [No Abstract]   [Full Text] [Related]  

  • 42. [Diabetes mellitus, cardiovascular sequelae and acarbose. Introductory Address by the German Diabetes Society].
    Schatz H
    Med Klin (Munich); 2003 Oct; 98 Suppl 1():20. PubMed ID: 14694839
    [No Abstract]   [Full Text] [Related]  

  • 43. Acarbose vs metformin for new-onset type 2 diabetes--author's reply.
    Yang W
    Lancet Diabetes Endocrinol; 2014 Feb; 2(2):105. PubMed ID: 24622708
    [No Abstract]   [Full Text] [Related]  

  • 44. [From control of impaired carbohydrate tolerance to primary prevention of atherosclerosis. Encouraging results of the STOP-NIDDM trial].
    Aronov DM; Bubnova MG
    Kardiologiia; 2003; 43(12):82-5. PubMed ID: 15035259
    [No Abstract]   [Full Text] [Related]  

  • 45. [Initial treatment of type 2 diabetes: metformin also for the Chinese!].
    Chanson P; Cordier JF; Pariente A
    Rev Prat; 2014 Apr; 64(4):470. PubMed ID: 24855777
    [No Abstract]   [Full Text] [Related]  

  • 46. [Acarbose for the treatment of impared glucose tolerance?].
    Carracedo E
    Gac Sanit; 2005; 19(3):265; author reply 265-6. PubMed ID: 15960964
    [No Abstract]   [Full Text] [Related]  

  • 47. [Acquired insensitivity to treatment with oral hypoglycemica in type 2 diabetes. Etiopathogenetic aspects].
    Motta L; Lombardo A; Trischitta V; Scavino S; Oliva G; Scornavacca G
    Minerva Endocrinol; 1984; 9(2):205-12. PubMed ID: 6503907
    [No Abstract]   [Full Text] [Related]  

  • 48. [New aspects of the treatment of non-insulin-dependent diabetes].
    Lesobre B
    Journ Annu Diabetol Hotel Dieu; 1987; ():335-8. PubMed ID: 3302490
    [No Abstract]   [Full Text] [Related]  

  • 49. Association between antidiabetic agents use and leukocyte telomere shortening rates in patients with type 2 diabetes.
    Liu J; Ge Y; Wu S; Ma D; Xu W; Zhang Y; Yang Y
    Aging (Albany NY); 2019 Jan; 11(2):741-755. PubMed ID: 30694216
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gut bacteria thwart the blood sugar-lowering effect of acarbose.
    Brauny MM; Maier L
    Nat Metab; 2023 May; 5(5):732-734. PubMed ID: 37157030
    [No Abstract]   [Full Text] [Related]  

  • 51. [Lipids and apolipoproteins at the time of onset of type 2 diabetes].
    Válek J; Brunová J; Grafnetter D; Vlasáková Z; Karasová L
    Cas Lek Cesk; 1988 Apr; 127(17):526-30. PubMed ID: 3396034
    [No Abstract]   [Full Text] [Related]  

  • 52. Non-insulin-dependent diabetes mellitus and Alzheimer's disease.
    Landi F; Bernabei R; Gambassi G
    J Am Geriatr Soc; 1997 May; 45(5):654-5. PubMed ID: 9158597
    [No Abstract]   [Full Text] [Related]  

  • 53. [The outlines of JEDIS-2, the new version of Japan Early Diabetes Intervension Study (JEDIS)].
    Kawazu S; Iwamoto Y; Kanazawa Y; Kuzuya T
    Nihon Rinsho; 2010 Nov; 68 Suppl 9():77-86. PubMed ID: 21667470
    [No Abstract]   [Full Text] [Related]  

  • 54. [Study of the hypoglycemic capacity of a thiadiazole derivative: 1395 Th in 60 diabetics].
    Debry G
    Ann Med Nancy; 1966 Jan; 5():70-7. PubMed ID: 5904217
    [No Abstract]   [Full Text] [Related]  

  • 55. [Clinical and biological study of a new hypoglycemic sulfonamide derivative of thiadiazole: TH 1395].
    Debry G; Cherrier P; Cuif G
    Diabete; 1966 Mar; 14(3):89-99. PubMed ID: 5931623
    [No Abstract]   [Full Text] [Related]  

  • 56. [Spectrum of apolipoproteins of blood serum in patients with non- insulin-dependent diabetes mellitus on acarbose treatment].
    Rosliakova LV; Roĭtman AP; Rakov SS; Ametov AS; Dolgov VV
    Klin Med (Mosk); 1999; 77(10):15-7. PubMed ID: 10635646
    [No Abstract]   [Full Text] [Related]  

  • 57. Combined treatment with exercise training and acarbose improves metabolic control and cardiovascular risk factor profile in subjects with mild type 2 diabetes.
    Wagner H; Degerblad M; Thorell A; Nygren J; Ståhle A; Kuhl J; Brismar TB; Ohrvik J; Efendic S; Båvenholm PN
    Diabetes Care; 2006 Jul; 29(7):1471-7. PubMed ID: 16801564
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of acarbose on postmeal mononuclear blood cell response in patients with early type 2 diabetes: the AI(I)DA study.
    Hanefeld M; Schaper F; Koehler C; Bergmann S; Ugocsai P; Stelzer J; Schmitz G
    Horm Metab Res; 2009 Feb; 41(2):132-6. PubMed ID: 19214923
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Changes in metabolic parameters and microalbuminuria in patients with type 2 diabetes treated with acarbose].
    González Sarmiento E; Ergueta Martín P; Fernández Martínez I; Hinojosa Mena-Bernal MC; Zurro Muñoz I; Zurro Hernández J
    An Med Interna; 2001 May; 18(5):234-6. PubMed ID: 11496556
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes.
    Zeymer U
    Int J Cardiol; 2006 Feb; 107(1):11-20. PubMed ID: 16337493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.